Published in Vaccine Weekly, July 13th, 2011
"We prospectively studied the immunogenicity of a monovalent adjuvanted influenza A/California/2009 (H1N1) vaccine (Pandemrix ®, GSK Biologicals, Rixen-sart, Belgium) in HD patients and controls. Antibody level was measured using a seroneutralization assay before (D-0) and 30 days after (D-30) a single 3.75 mu g...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly